Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB vs RB alternating with RBAC as induction therapy in elderly, transplant-ineligible mantle cell lymphoma
KCT0007009Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, bendamustine, cytarabine in mantle cell lymphoma (MCL), sponsored by Samsung Medical Center. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on KCT0007009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007009.